Glesatinib companion diagnostic - Guardant Health/Mirati Therapeutics

Drug Profile

Glesatinib companion diagnostic - Guardant Health/Mirati Therapeutics

Alternative Names: MGCD-265 companion diagnostic

Latest Information Update: 28 Apr 2016

Price : $50

At a glance

  • Originator Guardant Health
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Head and neck cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 17 Mar 2014 Clinical trials in Non-small cell lung cancer (diagnosis) in USA (unspecified route)
  • 17 Mar 2014 Clinical trials in Solid tumours (diagnosis) in Canada and USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top